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Abstract
Background: Dyslipidemia, particularly hypertriglyceridemia is common in uremia, and represents
an independent risk factor for atherosclerosis.
Methods: To investigate the effects of hemodialysis (HD) duration on very low density lipoprotein
(VLDL) and low density lipoprotein (LDL) compositions and lipopolytic activities, 20 patients on 5
to 7 years hemodialysis were followed-up during 9 years. Blood samples were drawn at T0
(beginning of the study), T1 (3 years after initiating study), T2 (6 years after initiating study) and T3
(9 years after initiating study). T0 was taken as reference.
Results: Triacylglycerols (TG) values were correlated with HD duration (r = 0.70, P < 0.05). An
increase of total cholesterol was noted at T2 and T3. Lowered activity was observed for
lipoprotein lipase (LPL) (-44%) at T3 and hepatic lipase (HL) (-29%) at T1, (-64%) at T2 and (-73%)
at T3. Inverse relationships were found between HD duration and LPL activity (r = -0.63, P < 0.05),
and HL activity (r = -0.71, P < 0.01). At T1, T2 and T3, high VLDL-amounts and VLDL-TG and
decreased VLDL-phospholipids values were noted. Increased LDL-cholesteryl esters values were
noted at T1 and T2 and in LDL-unesterified cholesterol at T2 and T3.
Conclusion: Despite hemodialysis duration, VLDL-LDL metabolism alterations are aggravated
submitting patients to a greater risk of atherosclerosis.
Background
Post heparin plasma contains at least two lipolytic
enzymes, lipoprotein lipase (EC 3.1.1.34, triacylglycerol-
protein acyl hydrolase) and hepatic triacylglycerol lipase
(EC 3.1.1.3, triacylglycerol acyl hydrolase). LPL is an ext-
rahepatic enzyme and exerts its hydrolytic activity on cir-
culating triacylglycerols (TG) carried by lipoproteins
associated with the surface bound apolipoprotein (apo)
C-II, a cofactor activator and involves the release of free
fatty acids which are taken up by tissues [1].
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Hepatic lipase is a hydrolytic enzyme, closely related, but
not identical to LPL. It is synthesized by the liver paren-
chymal cells but acts at the luminal wall of the liver sinu-
soids, in analogy with LPL. HL catalyses the hydrolysis of
triacylglycerols- (TG) and phospholipids- (PL) high den-
sity lipoprotein (HDL2) and TG-very low density lipopro-
tein (VLDL). There is also evidence that HL is mandatory
for the final conversion of intermediary density lipopro-
teins (IDL) to low density lipoproteins (LDL) [1].
Atherosclerosis is recognized as the major cause of cardio-
vascular disease (CVD) in hemodialysis and it is responsi-
ble for 40% to 50% of deaths in this population [2].
Patients with cardiac surgery, on dialysis have a high risk
of perioperative mortality and poor long term survival
rates [3]. It has been suggested that dialysis itself could
accelerate atherosclerosis and researchers agree that many
patients enter dialysis with atherosclerosis, which can lead
to a high risk of early mortality during the first years of
dialysis [4].
Dyslipidemia, is often observed in patients with chronic
renal failure (CRF), resulting in abnormal concentrations
and composition of plasma lipoproteins. The prominent
features of uremic dyslipidemia are an increase in plasma
triglycerides in nearly all lipoproteins, and a reduction in
high-density lipoprotein (HDL) cholesterol [5-7]. Hyper-
triglyceridemia is considered as an independent risk factor
for CVD [8] and is explained in CRF by a defective catab-
olism of triglyceride rich lipoproteins by the lipolytic
enzymes [9,10].
In hemodialysis patients, postheparin plasma LPL activity
and HL activity have been reported to be reduced, while
the apo CII/apo CIII ratio is decreased. A possible distur-
bance in both enzymes, accompanied by an increase in
apo CIII in VLDL, results in a prolonged half-life of the
VLDL particles, which may explain the observed hyper-
triglyceridemia in these patients [9-11].
However, the effects of long term hemodialysis on lipoly-
tic activities are not be clarified. There are many controver-
sies about the effects of dialysis duration on plasma lipid
metabolism. Some authors [9,10,12] have found that,
lipid and lipoprotein compositions do not appear to be
influenced by dialysis duration. Authors have not estab-
lish any relationships between plasma TG levels and dial-
ysis duration [9-13], whereas others have found
correlation between hypertriglyceridemia, cholesterol,
lecithin-cholesterol acyltransferase (LCAT) activity and
hemodialysis duration [14-17].
Based on these observations, a 9 years longitudinal study
was carried with the principal objective to evaluate the
effects of hemodialysis (HD) duration on plasma lipids,
lipoproteins and lipolytic activity alterations, in patients
with chronic renal failure. This effect was assessed by cor-
relation between duration of hemodialysis and lipolytic
activities and lipoproteins composition.
Methods
Subjects
Twenty CRF patients were taken for maintenance hemodi-
alysis during 9 years. Subjects were hemodialysed since 5
years at the beginning of the study. There were 6 women
and 14 men (37 ± 12 years) with a plasma creatinine and
urea values of 865 ± 231 μmol/L and 23 ± 4.85 mmol/L,
respectively. CRF causes were unknown in 20% of patients
and 80% had CRF secondary to chronic glomerulonephri-
tis. All patients were treated with vitamins, phosphate,
binding drugs and sodium bicarbonate for compensated
anorexia. No patient was treated with drugs known to
influence lipoprotein metabolism. Patients were dialysed
3 times weekly, using cuprophan membrane with a bicar-
bonate dialysate. The amount of delivered dialysis (Kt/V)
was 1.20 ± 0.18 and patients presented a mean interdia-
lytic body weight gain of 2.40 ± 1.17 kg, and received
intravenously 0.5 mg.kg-1 BW of heparin at the beginning
of the hemodialysis procedure and 0.25 mg.kg-1 BW each
hour.
All patients were treated at the Nephrology-Hemodialysis
ward of the University Hospital of Sidi Bel Abbes (west of
Algeria). The purpose of this study was explained to the
subjects and the investigation was carried out with their
written consent. The experimental protocol was approved
by the Committee for Research on Human Subjects of Sidi
Bel Abbes Hospital.
Assays
At the beginning of the study (T0) and at regular intervals
during follow-up of the same patients, blood samples
were drawn at four times, T0 (beginning of the study), T1
(3 years after initiating study), T2 (6 years after initiating
study) and T3 (9 years after initiating study). Results of the
T0 are taken as control. In all patients, blood was drawn
from the dialysis fistule at each time after a 12-hour over-
night fast. To obtain post-heparin plasma, blood samples
were obtained 10 min after the intravenous injection of
heparin (60 Units/kg). Plasma samples were collected by
low speed centrifugation at 3000 × g at 5°C, for 15 min,
preserved with 0.1% Na2 EDTA and 0.02% sodium azide
and divided into aliquots stored at -70°C until analysis.
Lipid analysis and insulin concentration
triacylglycerols (TG) and total cholesterol (TC) were
determined by specific colorimetric methods (Boehringer
Mannheim Gmbh, Kits, Germany). ELISA (Enzyme
Linked Immuno Sorbent) technique was used to deter-
mined insulin concentrations.BMC Cardiovascular Disorders 2009, 9:41 http://www.biomedcentral.com/1471-2261/9/41
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Lipolytic activity determination
plasma lipoprotein lipase (LPL) and hepatic lipase (HL)
activities were measured with direct and selective methods
[18] using as substrate a sonicated (3H)-trioleoglycerol
emulsion stabilized by phosphatidylcholines. One mU of
enzyme activity represented the release of 1 nmole fatty
acid per min at 37°C. Enzyme activity was expressed as
μmol of fatty acid. h-1. mL-1 of plasma.
Hepatic lipase activity was expressed as μmol of released
fatty acid. h-1. mL-1 of plasma. The LPL activity was calcu-
lated as described by Nilsson-Ehle and Schotz [19]. One
mU of enzymatic activity represented the release of 1
μmol fatty acid per min at 37°C.
Isolation and characterization of lipoprotein fractions
lipoproteins were isolated according to the method of
Havel et al [20]. VLDL and LDL were isolated from total
lipoproteins on a single spin discontinuous gradient [21],
then were dialysed against 0.15 M NaCl + 0.04% Na2
EDTA, pH 7.4 at 4°C in Spectra/Por dialysis tubing (Spec-
trum Medical Industries, Los Angeles, CA), for 24 h.
In each lipoprotein fraction, protein contents were deter-
mined using bovine serum albumin (Sigma Chemical
Company, St Louis, Mo) as standard [22]. Triacylglycerol,
total cholesterol (TC) and unesterified cholesterol (UC)
assays were performed by Boehringer reagent kits (Mey-
lan, France). Esterified cholesterol values were obtained
by difference between total cholesterol and unesterified
cholesterol amounts. Total phospholipids (PL) were
assayed by Wako reagent kit. VLDL was subjected to par-
tial lyophilisation, followed by rapid delipidation with
cold diethyl ether. For apolipoprotein (apo) C isolation,
electrophoresis was performed [23]. Sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE), with
2.5–20% acrylamide, was carried out at 25 V for 18 h.
After electrophoresis, apolipoproteins were stained with
coomassie brillant blue G250. The proportions of each
apolipoprotein were determined with the densitometer
tracing at 600 nm (densitometer Model Profil 26, Sebia,
Issy les Moulineaux, France). Results were expressed in
arbitrary units (AU).
Statistical analysis
Data are presented as the mean ± standard error, and were
initially analysed by ANOVA test. Differences were
assessed using Mann-Whitney test (non parametric). Lev-
els of P < 0.05 were taken as significant. Linear regression
analysis was used to determine correlation coefficients
between LPL, HL activities, VLDL and LDL compositions
and hemodialysis duration.
Results
Plasma triacylglycerol, total cholesterol and insulin 
concentrations
Patients showed a significant increase in triacylglycerol
concentrations according to HD duration (Table 1). In
hemodialysed patients, the TG values were higher 1.12-
fold at T1 (P < 0.05), 1.31-fold at T2 (P < 0.05) and 1.63-
fold at T3 (P < 0.01) than T0. No significant difference was
noted in TC concentrations in patients at T1 compared to
T0, but an increase by 14% and 33% was noted at T2 (P <
0.05) and T3 (P < 0.01), compared to T0. Insulin concen-
trations expressed in pg. L-1 plasma were increased in
hemodialysed patients, at T1 (P < 0.01), T2 (P < 0.001)
and T3 (P < 0.01), compared to T0.
Table 1: Plasma triacylglycerol, total cholesterol, insulin, apo C-II and apo C-III concentrations and lipoprotein lipase and hepatic 
lipase activities, in hemodialysed patients.
T0 T1 T2 T3
TG (mmol.L-1) 1.74 ± 0.17 1.96 ± 0.36* 2.29 ± 0.44* 2.84 ± 0.53**
TC (mmol.L-1) 3.56 ± 0.26 3.70 ± 0.22 4.07 ± 0.46* 4.76 ± 0.82**
Insulin (pg.L-1) 188 ± 23 209 ± 20** 223 ± 5*** 200 ± 15**
LPL(μmol fatty acids.L-1. h-1) 8.68 ± 1.94 7.80 ± 1.91 7.60 ± 0.80 4.88 ± 1,20***
HL(μmol fatty acids.L-1. h-1) 4.02 ± 1.43 2,86 ± 1.40*** 1,50 ± 0.40*** 1,09 ± 2,85***
ApoCII (AU) 18.59 ± 5.66 17.51 ± 5.37 16.25 ± 4.45* 14.99 ± 4.12**
ApoCIII (AU) 24.43 ± 8.17 27.93 ± 7.92 36.65 ± 7.40*** 50.51 ± 11.43***
Values are means ± SE. T0: Patients at the beginning of study, T1, T2 and T3: patients after 3, 6 and 9 years of the beginning of study, respectively. 
Comparison of the means was performed by ANOVA and using Mann-Whitney test: * T1, T2, T3 vs T0. * P < 0.05, ***P < 0.01, ***P < 0.001. LPL: 
Lipoprotein lipase, HL: Hepatic lipase, TG: Triacylglycerol, TC: Total cholesterol, Apo: Apolipoprotein, AU: Arbitrary units.BMC Cardiovascular Disorders 2009, 9:41 http://www.biomedcentral.com/1471-2261/9/41
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Lipolytic activities
Lipolytic activities were decreased in patients according to
HD duration (Table 1). A reduction in LPL activity by
about 44% was noted at T3 (P < 0.001), compared to T0.
HL activity was diminished by 29% at T1, 64% at T2 and
73% at T3 (P < 0.001), compared to T0.
Plasma apo C-II and apo C-III concentrations
Reduced apo C-II and increased apo C-III concentrations
(Table 1) were observed in patients, according to HD
duration. Compared to T0, apo C-II values were decreased
by 13% at T2 (P < 0.05) and 19% at T3 (P < 0.01). Apo C-
III values were higher 1.5-fold at T2 (P < 0.001) and 2.06-
fold at T3 (P < 0.001).
VLDL and LDL amounts and compositions
VLDL and LDL amounts, expressed in g.L-1 plasma, were
determined by adding their apolipoprotein and lipid
components concentrations (apolipoproteins (apo) + tri-
acylglycerols + unesterified cholesterol (UC) + cholesteryl
esters (CE) + phospholipids (PL)). Plasma VLDL amounts
were higher 3.2-fold at T1 (P < 0.01) and T2 (P < 0.01)
and 3.9-fold at T3 (P < 0.01), compared to T0 (Fig 1).
There was no significant difference in VLDL-apolipopro-
teins and VLDL-UC values according to HD duration,
while, VLDL-CE amounts were diminished by 76%, 80%
and 85% at T1 (P < 0.001), T2 (P < 0.001) and T3 (P <
0.001), respectively, compared to T0. VLDL-TG values
increased according to HD duration and were more ele-
vated at T1 (+9%) (P < 0.01), T2 (+30%) (P < 0.001) and
T3 (+63%) (P < 0.001), compared to T0. VLDL-PL concen-
trations diminished according to HD duration, and values
were progressively lowered at T1 (-49%) (P < 0.001), T2 (-
53%) (P < 0.001) and T3 (-59%) (P < 0.001), compared
to T0.
There was no significant difference in plasma, LDL-
amounts, -apolipoproteins, -TG and -phospholipids (Fig
2) values in patients according to HD duration. LDL-UC
concentrations were 3.6- and 4.2-fold higher at T2 (P <
0.001) and T3 (P < 0.001), respectively than T0. A signifi-
cant increase in LDL-CE was observed in patients and the
values were 2.1-, 2- and 1.8-fold higher at T1 (P < 0.01),
T2 (P < 0.01) and T3 (P < 0.05), respectively, compared to
T0.
Correlations analysis
Inverse relationships were found between HD duration
and LPL activity (r = -0.63, P < 0.05), and HL activity (r =
-0.71, P < 0.01). There was a positive correlation between
HD duration and TG amounts (r = 0.64, P < 0.01), VLDL-
amounts (r = 0.68, P < 0.01), VLDL-TG (r = 0.76, P < 0.01)
and inverse relationship was noted between HD duration
and VLDL-CE (r = -0.62, P < 0.01). No correlation was
found between HD duration and LDL amounts and com-
position.
Discussion
In order to determine the effects of long term hemodialy-
sis treatment on plasma VLDL and LDL amounts and
composition and lipolytic activities, a 9 years longitudinal
study was carried in CRF patients, on regular and suffi-
cient dialysis hemodialysed since 5 years at the beginning
of the study (T0). In this study triacylglycerol concentra-
tions were higher at each regular 3 years intervals and val-
ues were positively correlated with HD duration.
Moreover, enhanced plasma TC values were found at T2
and T3. VLDL amounts and composition tended to be
more increased with extensive hypertriglyceridemia and
HD duration. Hypertriglyceridemia is an independent risk
factor for CVD [8]. However, this hypertriglyceridemia
seemed to be moderate compared with developed coun-
tries homologous values. This could be due to the Medi-
terranean diet consumed by our population, which was
characterised by a high intake of vegetable proteins, com-
plex carbohydrates, fibre and monounsaturated fatty acids
[24].
Reduction of LPL activity in these patients was attributed
to its increased essential inhibitor cofactor apo-CIII and
diminished essential cofactor activator apo CII and hyper-
insulinemia [17]. Insulin is a principal hormone stimulat-
ing LPL activity, a functional insulin deficiency could play
an important role in this process in CRF [12]. Hyperin-
sulinemia disturb the activation of LPL and involve accu-
mulation of VLDL and LDL [14].
In the present study, LPL and HL activities reduction was
aggravated with HD duration. In contrast to some data
[10,11,13], we found a negative correlation between HD
duration, LPL and HL activities. LPL is activated by apo C-
II and inhibited by apo C-III, which can also inhibit HL
activity [10]. LPL activity was found [17] positively corre-
lated with hyperinsulinemia, thus contributing, with
increased apo C-III and reduced apo CII, to lowered LPL
activity. Moreover, in this study, reduced apo C-II concen-
trations were noted at T2. On the other hand, the fact that
our patients have adequate dialysis suggests that the
observed disturbances are caused by other mechanisms.
LPL hydrolyses TG carried by VLDL, and HL catalyses the
hydrolysis of HDL2-TG and HDL2-PL [25]. HL activity
reduction involves an increase in HDL2-TG and HDL2-PL.
Indeed, high PL- and TG-HDL2 and TG-HDL3 were previ-
ously found in CRF patients [26]. Considering the role of
LPL and HL in the lipolysis of plasma VLDL, impaired LPL
and HL activities can account for hypertriglyceridemia
[25], and increased VLDL concentrations [17]. These
results are confirmed in this study since VLDL amountsBMC Cardiovascular Disorders 2009, 9:41 http://www.biomedcentral.com/1471-2261/9/41
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Plasma VLDL amounts and compositions Figure 1
Plasma VLDL amounts and compositions. Values are means ± SE. T0: Patients at the beginning of study, T1, T2 and T3: 
patients after 3, 6 and 9 years of the beginning of study, respectively. Comparison of the means was performed by ANOVA and 
Mann-Whitney test: * T1, T2, T3 vs T0. * P < 0.05, ***P < 0.01, ***P < 0.001.
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Plasma LDL amounts and compositions Figure 2
Plasma LDL amounts and compositions. Values are means ± SE. T0: Patients at the beginning of study, T1, T2 and T3: 
patients after 3, 6 and 9 years of the beginning of study, respectively. Comparison of the means was performed by ANOVA and 
Mann-Whitney test: * T1, T2, T3 vs T0. * P < 0.05, ***P < 0.01, ***P < 0.001.
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and TG of VLDL and LDL were enhanced. Moreover,
decreased VLDL-cholesteryl esters might be related to the
low transfer of cholesteryl esters from HDL to VLDL and
of TG in the opposite direction, probably related to a
decreased cholesterol ester transfer protein (CETP) activ-
ity. VLDL-PL, which is the substrate for HL, was decreased
and this was probably due to the low HL activity. Several
mechanisms may explain the high plasma VLDL-amounts
and VLDL-TG concentrations. The LPL synthesis was
probably insufficient to hydrolyze the VLDL-TG, which
would explain the high plasma VLDL-amounts and VLDL-
TG concentrations in spite of unchanged LPL activity.
Indeed, this low LPL synthesis can be attributed to the
essential amino acids deficiency, knowing that our HD
patients had a food intake characterized by reduced ani-
mal proteins (<10% of total protein intake).
On the other hand, hemodialysis requires repeated use of
heparin, which reduces the reserve of the lipolytic
enzymes, facilitating their release from the endothelium
of blood vessels. This phenomenon could aggravate the
LPL deficiency, these enzymes are not normally synthe-
sized in uremic patients due to the resistance to the insu-
lin action.
Literature data about the effect of HD duration on dyslip-
idemia generated by CRF are few and controversy. Our
results differed from those of some authors who found
that lipid and lipoprotein compositions did not appear to
be influenced by dialysis duration in CRF patients [9-11].
However, these authors did not specify the dialysis dura-
tion in their patients, except by the statement that it was
over 3 months. Ifudu et al [12] did not found any change
in triglycerides and cholesterol concentrations according
to increased HD duration, in patients hemodialyed for
10–24 years. However, the increase in triglyceride and
cholesterol concentrations was positively correlated with
the HD duration in the study of Sobh et al. [14]. Moreo-
ver, Paragh et al [15] showed that plasma triglycerides
were positively correlated with HD duration, in patients
hemodialysed during 8 to 181 weeks. In our study,
plasma triglycerides, cholesterol, LPL, HL activities and
VLDL-LDL compositions appeared clearly altered by HD
duration. The evolutive lipid profile seemed to be more
atherogenic and thus contributing to high cardiovascular
risk.
Conclusion
The results of this study demonstrates that in CRF patients
treated by intermittent dialysis, long-term hemodialysis
fails to correct dyslipidemia generated by CRF. Hypertrig-
lyceridemia, increases of VLDL-amounts, VLDL-TG and
VLDL-CE and reduction of LPL and HL activities are corre-
lated with HD duration. Long term hemodialysis does not
improve LDL-TG increase and LDL-PL decrease; moreover
long term hemodialysis lowers apo C-II and enhances apo
CIII and VLDL-CE. It can be suggested that patients on
hemodialysis are particularly prone to atherosclerosis risk
and that long term hemodialysis itself may worsen this
condition. Dialysis can effectively reduce the accumula-
tion of nitrogenous metabolites and correct disturbed
fluid and electrolyte homeostasis, but patients on dialysis
are still exposed to several of the metabolic consequences
of renal failure. It could appear highly advantageous to
reduce complication of long term dialysis patients with
preventing modalities. Patients could benefit from
decreased prevalence of cardiovascular and atheroscle-
rotic diseases.
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